Skip to content
10-Q

Quarterly Report

Adverum Biotechnologies, Inc.

0001628280-24-045033

← back to feed
Filed
Nov 4, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Oct 31, 2024 20.8M sh
Short Term Investments Q3 2024 · Sep 30, 2024 $60.39M
Short Term Investments Q3 2024 · Dec 31, 2023 $21.53M
Current Liabilities Q3 2024 · Sep 30, 2024 $27.66M
Current Liabilities Q3 2024 · Dec 31, 2023 $24.91M
Total Liabilities Q3 2024 · Sep 30, 2024 $90.26M
Total Liabilities Q3 2024 · Dec 31, 2023 $89.54M
Current Assets Q3 2024 · Sep 30, 2024 $161.08M
Current Assets Q3 2024 · Dec 31, 2023 $102.77M
Total Assets Q3 2024 · Sep 30, 2024 $234.38M
Total Assets Q3 2024 · Dec 31, 2023 $173.01M
Cash And Equivalents Q3 2024 · Dec 31, 2023 $75M
Cash And Equivalents Q3 2024 · Sep 30, 2023 $105.37M
Shares Diluted restated Q3 2024 · Sep 30, 2023 10.1M sh
Shares Diluted restated Q3 2024 · Sep 30, 2023 10.07M sh
Capex Q3 2024 · Sep 30, 2023 $616K
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$69.57M
Stockholders Equity Q3 2024 · Sep 30, 2023 $102.71M
Stockholders Equity Q3 2024 · Jun 30, 2023 $131.16M
Stockholders Equity Q3 2024 · Mar 31, 2023 $157.76M
Stockholders Equity Q3 2024 · Dec 31, 2022 $181.52M
Eps Diluted restated Q3 2024 · Sep 30, 2023 −$3.26
Eps Diluted restated Q3 2024 · Sep 30, 2023 −$9.28
Eps Basic restated Q3 2024 · Sep 30, 2023 −$3.26
Eps Basic restated Q3 2024 · Sep 30, 2023 −$9.28
Sga Expense Q3 2024 · Sep 30, 2023 $13.79M
Sga Expense Q3 2024 · Sep 30, 2023 $39.04M
Rd Expense Q3 2024 · Sep 30, 2023 $20.74M
Rd Expense Q3 2024 · Sep 30, 2023 $62.4M
Net Income Q3 2024 · Sep 30, 2023 −$32.89M
Net Income Q3 2024 · Sep 30, 2023 −$93.45M
Net Income Q3 2024 · Jun 30, 2023 −$31.51M
Net Income Q3 2024 · Mar 31, 2023 −$29.06M
Operating Income Q3 2024 · Sep 30, 2023 −$34.53M
Operating Income Q3 2024 · Sep 30, 2023 −$97.83M
Revenue Q3 2024 · Sep 30, 2023 $0
Revenue Q3 2024 · Sep 30, 2023 $3.6M